Dimerix clears path for $36M debt facility with related-party lender
What's the deal? Dimerix BiosciencesDealroom has a profile for this one. Try Dealroom →, a Melbourne-based clinical-stage biopharmaceutical company, has secured a debt facility of up to US$32.4M (roughly $36 million) that includes funding from related-party lender Skiptan. An ASXDealroom has a profile for this one. Try Dealroom → waiver of Listing Rule 10.1 lets it grant security over its assets to Skiptan without shareholder approval.
The mechanics: Dimerix has access to US$22M so far, split between US$14.2M from unrelated lenders and US$7.76M from Skiptan. It has initially drawn down half of those committed funds.
Why now? The company develops treatments for kidney disease and targets non-dilutive funding to support its late-stage development programs. Its board, backed by external advisers, judged the Skiptan facility the most favourable option versus a discounted equity raise.
What could go wrong? Borrowing from a substantial shareholder raises governance questions. To address that, ASX conditioned the waiver on disclosure of the facility's material terms, security arrangements, and Dimerix's rationale for using Skiptan as lender.
The board determined all loan agreements were negotiated on arm's length, fair and reasonable terms for ordinary shareholders. Dimerix carries a market capitalisation of US$95.2M, and the most recent analyst rating on the stock is a Buy with a US$0.94 price target.
The signal: The structure shows how cash-hungry clinical-stage biotechs are leaning on debt and insider capital to fund late-stage trials without diluting existing holders — trading equity dilution for the scrutiny that comes with related-party lending.
Read more: tipranks.com
Image credit: Generated with Gemini
